|
**Overview**:**Varicella Zoster Virus(VZV) IgG & IgM Panel****Introduction**: The Varicella Zoster Virus Antibodies Panel IgG IgM (VZV Ab IgG IgM) Panel is a diagnostic tool designed for varicella infection screening using serum samples. In India, varicella (chickenpox) remains common in children (~90 percent seropositivity by adulthood), with adult primary infection or reactivation (herpes zoster) causing significant morbidity in immunocompromised, elderly, or pregnant individuals (congenital varicella syndrome risk if maternal infection in first trimester). High morbidity from under-testing in rural/low-SES pregnant women or immunocompromised patients with rash/fever, limited serology labs, delayed acyclovir or VZIG leading to severe complications or fetal defects. Per infectious disease practices aligned with ICMR, Indian Academy of Pediatrics, and FOGSI guidelines, the test employs immunoassay for VZV IgG and IgM over 1â€"2 days with high accuracy, valuable for immunity assessment (IgG positive = past infection/vaccination) and acute diagnosis (IgM positive). This diagnostic falls under infectious disease screening and targets pregnant women, immunocompromised patients, or pre-vaccination status check, addressing accurate detection to guide prophylaxis or treatment. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise VZV profiling and reducing congenital/complicated varicella burden. Its serum-based approach ensures reliable IgG/IgM assessment.**Other Names**: VZV Ab Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: VZV IgG/IgM standard in pregnancy/immunocompromised screening; in India, routine in high-risk antenatal.**Purpose**: The test assesses 2 parameters including VZV IgG to guide varicella screening, assess immunity/acute infection, inform prophylaxis.**Test Parameters**: 1. VZV IgG, 2. VZV IgM.**Pretest Condition**: No fasting required; patients should have rash or risk factors.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on rash, pregnancy, immunosuppression.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected VZV including fetal defects, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM indicates acute infection; IgG positive immunity, necessitating specialist input.**Specialist Consultation**: Infectious disease specialists or obstetricians should be consulted for management.**Additional Supporting Tests**: PCR on lesion swab for confirmation.**Test Limitations**: IgM false positives possible; comprehensive approach required.**References**: Indian Journal of Dermatology 2024, VZV Studies India 2023. |
